L & L International Holdings, Inc. (OTC BB: LLFH)
L & L International Holdings, Inc. (OTC BB: LLFH) is a US public traded company that serves as a bridge…
Blog
Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI)
Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) is focused on commercializing patent-protected disruptive healthcare technologies specifically designed to take leading roles for…
Adherex Technologies, Inc. (AMEX: ADH)
Adherex Technologies, Inc. (AMEX: ADH), a biopharmaceutical company, is focused on discovering and developing novel cancer therapeutics. They currently have…
Access Pharmaceuticals, Inc. (OTC BB: ACCP)
Access Pharmaceuticals, Inc. (OTC BB: ACCP), an emerging biopharmaceutical company, is committed to the development and commercialization of propriety products…
Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI)
Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) is focused on commercializing patent-protected disruptive healthcare technologies specifically designed to take leading roles for…
ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD)
ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD), a biopharmaceutical company, is focused on utilizing innovative technology to stimulate drug discovery and clinical…
Aastrom Biosciences, Inc. (NASDAQ: ASTM)
Aastrom Biosciences, Inc. (NASDAQ: ASTM) is focused on the development of autologous cell products for the repair or regeneration of…
A.P. Pharma, Inc. (NASDAQ: APPA)
A.P. Pharma, Inc. (NASDAQ: APPA), a specialty pharmaceutical company, is committed to developing ethical (prescription) pharmaceuticals through the utilization of…
Kona Grill, Inc. (KONA) Announces Third Quarter Financial Results; CEO Comments on Fourth Quarter and Year-End Outlook
Kona Grill, Inc. (NASD: KONA), an American grill and sushi bar, recently announced its financial results for the third quarter…
Provectus Pharmaceuticals, Inc. (PVCT.OB) Introduces New Center as Phase 2 Begins for Leading Oncology Agent
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT) announced that they have commenced recruitment for their Phase 2 clinical trial of the…